Nuvation Bio Inc. (NUVB)
2.59
-0.08 (-3.00%)
At close: Jan 14, 2025, 3:59 PM
2.59
0.00%
After-hours Jan 14, 2025, 07:00 PM EST
undefined% (undefined)
| Bid | 2.3 |
| Market Cap | 871.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -1.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.8 |
| Volume | 2,747,563 |
| Avg. Volume (20D) | 2,357,398 |
| Open | 2.64 |
| Previous Close | 2.67 |
| Day's Range | 2.50 - 2.64 |
| 52-Week Range | 1.43 - 4.16 |
| Beta | undefined |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiat...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2020
Employees 203
Stock Exchange NYSE
Ticker Symbol NUVB
Website https://www.nuvationbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 170.27% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
+14.44%
Nuvation Bio shares are trading higher after RBC C...
Unlock content with
Pro Subscription
5 months ago ·
Source
-5.36%
Nuvation Bio shares are trading lower. The company reported Q2 financial results.
